(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.
(CIDRAP News) The genetic blueprint of Coxiella burnetii, a category B bioterrorism agent that causes Q fever, has been decoded and analyzed, the National Institute of Allergy and Infectious Diseases (NIAID) announced this week.
(CIDRAP News) – The US Department of Health and Human Services yesterday announced $350 million in grants for eight regional centers to lead and coordinate research on defenses against bioterrorism and emerging infectious diseases.
(CIDRAP News) Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.
(CIDRAP News) Federal health officials yesterday announced grants to build 11 new biodefense laboratories around the country, including two that will be authorized to study the most dangerous pathogens.
(CIDRAP News) Albany Medical College in Albany, N.Y., has received an $8.3 million federal grant to study pulmonary tularemia, with the main emphasis on developing a vaccine, college officials announced last week.
The grant from the National Institute of Allergy and Infectious Diseases (NIAID) will fund tularemia research at the college for 4½ years, the college said in a news release.
(CIDRAP News) The Food and Drug Administration (FDA) this week published guidelines for the development of drugs to treat the side effects of smallpox vaccination, an area in which the federal government is investing substantial research funds.
(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has awarded contracts worth more than $73 million to study the mechanisms by which certain infectious agents, including potential bioterror agents, trigger immune reactions, the National Institutes of Health (NIH) announced yesterday.
Editor's note: A correction was made in this story Nov 9 to note that the existing licensed anthrax vaccine contains the natural rather than recombinant form of anthrax protective antigen.
(CIDRAP News) Federal health officials today announced the award of an $877 million contract for 75 million doses of a new anthrax vaccine to protect the public and improve on the existing vaccine used by the military.